Modular Medical (MODD) S-1/A 9 Feb 22 IPO registration (amended) Financial data

Cover

Cover	6 Months Ended
	Sep. 30, 2021
Cover [Abstract]
Document Type	S-1/A
Amendment Flag	true
Amendment Description	The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act, or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.
Entity Registrant Name	MODULAR MEDICAL, INC.
Entity Central Index Key	0001074871
Entity Tax Identification Number	87-0620495
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	16772 W. Bernardo Drive
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92127
City Area Code	(858)
Local Phone Number	800-3500
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2021	Mar. 31, 2021	Mar. 31, 2020
CURRENT ASSETS
Cash and cash equivalents	$ 798,161	$ 1,468,465	$ 3,122,134
Prepaid expenses	43,580	178,158	63,853
Other current assets	2,920	2,466	306
TOTAL CURRENT ASSETS	844,661	1,649,089	3,186,293
Property and equipment, net	268,138	298,958	301,308
Right of use asset, net	162,039	200,124	270,950
Security deposit	100,000	100,000	100,000
TOTAL NON-CURRENT ASSETS	530,177	599,082	672,258
TOTAL ASSETS	1,374,838	2,248,171	3,858,551
CURRENT LIABILITIES
Accounts payable	692,772	169,284	367,019
Accrued expenses	678,797	499,948	202,160
Short-term lease liability	134,914	125,500	92,214
PPP note payable		368,780
Convertible notes payable	4,855,260	2,133,453
TOTAL CURRENT LIABILITIES	6,361,743	3,296,965	661,393
LONG-TERM LIABILITIES
Long-term lease liability	113,909	184,355	178,736
Bonus payable		42,000	140,000
TOTAL LIABILITIES	6,475,652	3,523,320	980,129
STOCKHOLDERS’ EQUITY (DEFICIT)
Preferred Stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding
Common Stock, $0.001 par value, 50,000,000 shares authorized, 6,302,050 shares and 5,956,754 shares issued and outstanding as of March 31, 2021 and 2020, respectively	6,328	6,302	5,957
Additional paid-in capital	20,056,716	14,665,559	10,517,505
Accumulated deficit	(25,163,858)	(15,947,010)	(8,569,034)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	(5,100,814)	(1,275,149)	2,878,422
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	1,374,838	2,248,171	3,858,551
Common stock issuable			923,994
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$ 1,374,838	$ 2,248,171	$ 3,858,551

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2021	Mar. 31, 2021	Mar. 31, 2020
Statement of Financial Position [Abstract]
Preferred Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Preferred Stock, Shares Authorized		5,000,000	5,000,000
Preferred Stock, Shares Outstanding		0	0
Common Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Common Stock, Shares Authorized		50,000,000	50,000,000
Common Stock, Shares, Outstanding	6,327,521	6,302,050	5,956,754
Preferred Stock, Shares Issued		0	0
Common Stock, Shares, Issued		6,302,050	5,956,754

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2021	Mar. 31, 2020
Operating expenses
Research and development	$ 2,105,380	$ 1,092,665	$ 3,893,511	$ 2,063,480	$ 4,083,303	$ 3,034,152
General and administrative expenses	1,589,032	766,513	3,174,489	1,669,910	3,253,412	2,313,870
Total operating expenses	3,694,412	1,859,178	7,068,000	3,733,390	7,336,715	5,348,022
Loss from operations	(3,694,412)	(1,859,178)	(7,068,000)	(3,733,390)	(7,336,715)	(5,348,022)
Other income	48	49	368,872	104
Interest expense	(685,793)		(1,194,670)		(39,791)
Loss on debt extinguishment			(1,321,450)
Loss before income taxes	(4,380,157)	(1,859,129)	(9,215,248)	(3,733,286)	(7,376,376)	(5,319,273)
Provision for income taxes	1,600	1,600	1,600	1,600	1,600	1,600
Net loss	$ (4,381,757)	$ (1,860,729)	$ (9,216,848)	$ (3,734,886)	$ (7,377,976)	$ (5,320,873)
Net loss per share
Basic and diluted	$ (0.69)	$ (0.30)	$ (1.46)	$ (0.61)	$ (1.19)	$ (0.89)
Shares used in computing net loss per share
Basic and diluted	6,323,925	6,200,053	6,320,916	6,156,602	6,211,562	5,954,923
Interest income					$ 130	$ 28,749
Loss before income taxes	$ (4,380,157)	$ (1,859,129)	$ (9,215,248)	$ (3,733,286)	$ (7,376,376)	$ (5,319,273)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock Issuable	Retained Earnings [Member]	Total
Beginning balance, value at Mar. 31, 2019	$ 5,947	$ 9,696,471	$ 19,800	$ (3,248,161)	$ 6,474,057
Shares, Outstanding, Beginning Balance at Mar. 31, 2019	5,946,754
Shares issued for services	$ 10	19,790	(19,800)
Stock Issued During Period, Shares, Issued for Services	10,000
Net loss				(5,320,873)	(5,320,873)
Ending balance, value at Mar. 31, 2020	$ 5,957	10,517,505	923,994	(8,569,034)	2,878,422
Shares, Outstanding, Ending Balance at Mar. 31, 2020	5,956,754
Placement of common stock			923,994		923,994
Stock-based compensation		801,244			801,244
Stock-based compensation		344,716			344,716
Net loss				(1,874,157)	(1,874,157)
Ending balance, value at Jun. 30, 2020	$ 6,200	12,904,606		(10,443,191)	2,467,615
Shares, Outstanding, Ending Balance at Jun. 30, 2020	6,200,053
Placement of common stock	$ 243	2,042,385	(923,994)		1,118,634
Stock Issued During Period, Shares, New Issues	243,299
Beginning balance, value at Mar. 31, 2020	$ 5,957	10,517,505	923,994	(8,569,034)	2,878,422
Shares, Outstanding, Beginning Balance at Mar. 31, 2020	5,956,754
Warrants issued with convertible notes
Stock-based compensation					645,320
Net loss					(3,734,886)
Ending balance, value at Sep. 30, 2020	$ 6,200	13,205,210		(12,303,920)	907,490
Shares, Outstanding, Ending Balance at Sep. 30, 2020	6,200,053
Beginning balance, value at Mar. 31, 2020	$ 5,957	10,517,505	923,994	(8,569,034)	2,878,422
Shares, Outstanding, Beginning Balance at Mar. 31, 2020	5,956,754
Shares issued for services	$ 24	210,920			210,945
Stock Issued During Period, Shares, Issued for Services	24,500
Net loss				(7,377,976)	(7,377,976)
Ending balance, value at Mar. 31, 2021	$ 6,302	14,665,559		(15,947,010)	(1,275,149)
Shares, Outstanding, Ending Balance at Mar. 31, 2021	6,302,050
Placement of common stock	$ 321	2,709,555	(923,994)		1,785,882
Stock Issued During Period, Shares, New Issues	320,796
Stock-based compensation		1,227,578			1,227,578
Beginning balance, value at Jun. 30, 2020	$ 6,200	12,904,606		(10,443,191)	2,467,615
Shares, Outstanding, Beginning Balance at Jun. 30, 2020	6,200,053
Stock-based compensation		300,604			300,604
Net loss				(1,860,729)	(1,860,729)
Ending balance, value at Sep. 30, 2020	$ 6,200	13,205,210		(12,303,920)	907,490
Shares, Outstanding, Ending Balance at Sep. 30, 2020	6,200,053
Beginning balance, value at Mar. 31, 2021	$ 6,302	14,665,559		(15,947,010)	(1,275,149)
Shares, Outstanding, Beginning Balance at Mar. 31, 2021	6,302,050
Shares issued for services	$ 20	172,180			172,200
Stock Issued During Period, Shares, Issued for Services	20,000
Warrants issued with convertible notes		3,700,632			3,700,632
Stock-based compensation	$ 2	655,918			655,920
Stock-based compensation, Shares	1,836
Net loss				(4,835,091)	(4,835,091)
Ending balance, value at Jun. 30, 2021	$ 6,324	19,194,289		(20,782,101)	(1,581,488)
Shares, Outstanding, Ending Balance at Jun. 30, 2021	6,323,886
Beginning balance, value at Mar. 31, 2021	$ 6,302	14,665,559		(15,947,010)	(1,275,149)
Shares, Outstanding, Beginning Balance at Mar. 31, 2021	6,302,050
Warrants issued with convertible notes					3,700,632
Stock-based compensation					1,518,351
Stock-based compensation, Shares	5,472
Net loss					(9,216,848)
Ending balance, value at Sep. 30, 2021	$ 6,328	20,056,716		(25,163,858)	(5,100,814)
Shares, Outstanding, Ending Balance at Sep. 30, 2021	6,327,521
Stock Issued During Period, Shares, New Issues	20,000
Beginning balance, value at Jun. 30, 2021	$ 6,324	19,194,289		(20,782,101)	(1,581,488)
Shares, Outstanding, Beginning Balance at Jun. 30, 2021	6,323,886
Stock-based compensation	$ 4	862,427			862,431
Stock-based compensation, Shares	3,365
Net loss				(4,381,757)	(4,381,757)
Ending balance, value at Sep. 30, 2021	$ 6,328	$ 20,056,716		$ (25,163,858)	$ (5,100,814)
Shares, Outstanding, Ending Balance at Sep. 30, 2021	6,327,521

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2021	Mar. 31, 2020
Statement of Cash Flows [Abstract]
Net loss	$ (9,216,848)	$ (3,734,886)	$ (7,377,976)	$ (5,320,873)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on PPP note forgiveness	(368,780)
Loss on debt extinguishment	1,321,450
Stock-based compensation expense	1,518,351	645,320
Depreciation and amortization	53,599	52,314	111,015	35,431
Shares for services	314,265		68,880
Amortization of lease right-of-use asset	38,085	35,923	70,826
Change in lease liability	(61,032)	94,518	38,905
Amortization of debt issuance costs	824,439		12,253
Changes in assets and liabilities:
Prepaid expenses and other assets	(7,941)	28,659
Accounts payable and accrued expenses	799,687	(151,519)	(86,747)	530,250
Net cash used in operating activities	(4,784,725)	(3,029,671)	(5,908,662)	(4,094,839)
Cash flows from investing activities
Purchases of property and equipment	(22,779)	(93,303)	(109,669)	(260,789)
Net cash used in investing activities	(22,779)	(93,303)	(109,669)	(260,789)
Cash flows from financing activities
Proceeds from private placement, net of issuance costs		1,118,634	1,785,882	923,994
Proceeds from issuance of convertible notes	4,137,200		2,210,000
Proceeds from issuance of PPP note payable		368,780	368,780
Net cash provided by financing activities	4,137,200	1,487,414	4,364,662	923,994
Net decrease in cash and cash equivalents	(670,304)	(1,635,560)	(1,653,669)	(3,431,634)
Cash and cash equivalents, at beginning of year	1,468,465	3,122,134	3,122,134	6,553,768
Cash and cash equivalents, at end of year	798,161	1,486,574	1,468,465	3,122,134
Noncash investing and financing activities:
Fair value of detachable warrants issued with convertible notes	3,700,632
Stock-based compensation expense			1,227,578	801,244
Other			1,004
Other assets and prepaid expenses			25,600	(48,391)
Security deposits				(92,500)
Net decrease in cash and cash equivalents	$ (670,304)	$ (1,635,560)	(1,653,669)	(3,431,634)
Income taxes			$ 1,600	$ 1,600

THE COMPANY AND SUMMARY OF SIGN

THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Modular Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras acquired in the merger, at their historical carrying amounts. Prior to the acquisition of Quasuras and since at least 2002, the Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act). In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc. The Company is a development-stage, medical-device company focused on the design, development, and commercialization of an innovative insulin pump using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part, patch pump product, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care that presently available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, the Company seeks to expand the wearable insulin delivery device market beyond the highly motivated “super users” and expand the category into the mass market. The Company’s pump product seeks to serve both the type 1 and type 2 diabetes markets. Liquidity Financial Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15), Going Concern The Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent commercialization of its product. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant product revenues to achieve profitability. The Company’s expected operating losses and cash burn and the need to repay the convertible promissory notes and accrued interest in the first half of 2022 raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. As disclosed in note 9, the Company recently sold shares of its common stock to two of its officers, obtained access to a credit facility and filed a registration statement to offer shares of its common stock. The Company’s operating needs include the planned costs to operate its business, including amounts required to repay its convertible promissory notes (if not converted), fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. These condensed consolidated financial statements do not include any adjustments that might result from this uncertainty. Basis of Presentation The Company’s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2022 refers to the fiscal year ending March 31, 2022). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation. The accompanying condensed consolidated financial statements of the Company have been prepared without audit. The condensed consolidated balance sheet as of March 31, 2021 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending March 31, 2022 or for any other future period. All share and per share amounts have been presented to give retroactive effect to a 1-for-3 reverse stock split that occurred in November 2021. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates. Reportable Segment The Company operates in one Research and Development The Company expenses research and development expenditures as incurred. General and Administrative General and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees, and office and other administrative expenses. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash balances at high-quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial institution failure. Risks and Uncertainties The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing technology and customer requirements, limited operating history and the volatility of public markets. COVID-19 The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and highly liquid debt instruments with original maturities of three months or less. Property & Equipment Property and equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three five Fair Value of Financial Instruments The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: · Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. · Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. · Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement. Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses approximate fair value. Per-Share Amounts Basic net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. For the six months ended September 30, 2021 and 2020, outstanding options to purchase 1,597,650 1,160,030 Reclassification Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and six months ended September 30, 2021 and 2020, the Company’s comprehensive loss was the same as its net loss. Recently Adopted Accounting Pronouncement In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an Entity’s Own Equity .	Note 1 – THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Modular Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the merger, at their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act). In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc. The Company is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative insulin pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps for insulin-dependent people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent diabetes to receive their daily insulin in two ways, through a continuous “basal” delivery allowing a small amount of insulin to be in the blood at all times and a “bolus” delivery to address meal time glucose input and to address when the blood glucose level becomes excessively high. By addressing the time and effort required to effectively treat their condition, the Company believes it can address the less technically savvy, less motivated part of the market. The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America. The following summarizes the more significant of such policies: Liquidity Financial Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15), Going The Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent commercialization of its product. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. As discussed in notes 3 and 11, in February 2021, the Company commenced a private placement of its convertible promissory notes to investors to fund its operations. In addition, during fiscal 2021, the Company obtained additional equity financing through a private placement of its common stock (see note 6), and the Company obtained a loan from Silicon Valley Bank in April 2020 (see notes 3 and 12). The Company’s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. These consolidated financial statements do not include any adjustments that might result from this uncertainty. Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on March 31 of each calendar year. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates. Reportable Segment The Company operates in one business segment and uses one measurement of profitability for its business. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are deposited with high credit-quality institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000. Risks and Uncertainties The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets. COVID-19 The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted. Cash and Cash Equivalents Cash and cash equivalents include cash in hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. Property and Equipment Property and equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three five Fair Value of Financial Instruments The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: · Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. · Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. · Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement. Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value. Research and Development The Company expenses research and development expenditures as incurred. General and Administrative General and administrative expense consists primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and meetings and travel. Stock-Based Compensation The Company recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and projected stock option exercise behaviors. Per-Share Amounts Basic net loss per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. For the years ended March 31, 2021 and 2020, 1,197,252 1,059,315 Income Taxes The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance. The Company accounts for uncertain tax positions in accordance with FASB Accounting Standards Codification (ASC) Topic 740, Income Taxes The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns from 2016 to 2020 may be subject to examination by the U.S. federal and state tax authorities. As of March 31, 2021, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2021 and 2020, the Company’s comprehensive loss was the same as its net loss.

LEASES

LEASES	6 Months Ended	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Leases [Abstract]
LEASES	NOTE 2 – LEASES Effective April 1, 2019, the Company adopted ASU No. 2016-02, Leases 39 12,400 3% The Company obtained a right-of-use asset of $ 270,950 139,000 Future minimum payments under the facility operating lease, as of September 30, 2021, are listed in the table below. Operating Annual Fiscal Years lease 2022 76,716 2023 158,028 2024 40,692 Less: Imputed interest (26,613 ) Present value of lease liabilities $ 248,823 Cash paid for amounts included in the measurement of lease liabilities was $ 76,716 53,768 53,768 26,884 26,844	NOTE 4 – LEASES Effective April 1, 2019, the Company adopted ASC No. 842, as amended, using the alternative transition method, which allowed the Company to initially apply the new lease standard at the adoption date (the “effective date method”). In January 2020, the Company executed a lease for a new, larger corporate facility in San Diego, California and paid a $100,000 security deposit. 39 12,400 with annual rent increases of approximately 3% . In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. The right-to-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease payments. A discount rate of 11%, which approximated the Company’s incremental borrowing rate, was used to measure the lease asset and liability. Lease expense is recognized on a straight line basis over the lease term. The Company obtained a right-of-use asset of $ 270,950 139,000 Future minimum payments under the facility operating lease, net of the lease incentive Operating Annual Fiscal Years lease 2022 $ 153,432 2023 158,028 2024 40,692 Less: Imputed interest (42,297 ) Present value of lease liabilities $ 309,855 Rent expense was $ 107,540 35,766

PPP NOTE

PPP NOTE	6 Months Ended
	Sep. 30, 2021
Ppp Note
PPP NOTE	NOTE 3 – PPP NOTE On April 24, 2020, the Company received a $ 368,780 The Company applied to the Lender for forgiveness of the PPP Note in October 2020, and, in May 2021, the Company was notified by the Lender and the U.S. Small Business Administration that the outstanding principal and accrued interest for the PPP Note was forgiven in full. The Company accounted for the forgiveness of the PPP Note in accordance with Accounting Standards Codification Topic 470: Debt (ASC 470), and the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the condensed consolidated statement of operations.

CONVERTIBLE PROMISSORY NOTES

CONVERTIBLE PROMISSORY NOTES	6 Months Ended	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Debt Disclosure [Abstract]
CONVERTIBLE PROMISSORY NOTES	NOTE 4 – CONVERTIBLE PROMISSORY NOTES From February through April 2021, the Company sold $2,310,000 of convertible promissory notes (each an Original Notes and, collectively, the Original Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between each holder of an Original Note and the Company (the Revocation Agreement), the $2,310,000 of Original Notes and accrued interest thereon as of April 30, 2021 were replaced with $2,360,550 aggregate principal amount of new Notes (as defined below). The Company accounted for the replacement of the Original Notes in accordance with ASC 470 and recorded a loss on extinguishment of $ 1,321,450 70,647 In April and May 2021, pursuant to a Securities Purchase Agreement by and between the Company and each investor (the SPA), the Company sold to investors $ 4,250,000 th Notes outstanding after the Trigger Date may be converted into shares of the Company’s common stock at an initial conversion price of $8.61 per share; provided that a Note holder may not convert any portion of its Note that would cause it to beneficially own in excess of 4.99% of the Company’s outstanding common stock. The conversion price and number of shares of Company common stock issuable upon conversion of the Notes are subject to adjustment from time to time for subdivisions and consolidations of shares and other standard dilutive and corporate events, as provided in the Notes. Subject to certain Exempt Issuances (as defined in the Notes), if while a Note is outstanding, the Company sells, issues or grants any shares of its common stock or other securities to acquire shares of common stock at a price per share less than the then conversion price, such conversion price shall be reduced to such lesser price, and the number of conversion shares issuable upon conversion of the Notes shall be increased, as provided in the Notes. If the Company completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital Raise, as defined in the Notes), each Note holder will be required to convert its Adjusted Note Amount (as defined below) into the securities of such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued interest on a Note, multiplied by (ii) 1.25. The Notes contain a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal or interest thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v) material restatements of the Company’s consolidated financial statements filed with the SEC, (vi) a holder’s inability to rely on Rule 144 for sales of shares underlying the Notes, (vii) the Company’s common stock is suspended or halted from trading and/or fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the Nasdaq Stock Market, the New York Stock Exchange, or the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement covering the resale of shares of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date, (ix) failure to cause such registration statement to become effective within 120 calendar days following the Issue Date, or (x) certain mergers consolidations, business combinations and sales of all or substantially all of the Company’s assets in the event the Company is not the survivor of such transaction. Upon an Event of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required to pay such Note holder the sum of (i) the product of (a) all then outstanding principal amount and accrued interest thereon, multiplied by (b) 125%; and (ii) all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder, in the event the Company receives cash proceeds as a result of certain events, including, but not limited to, payments from customers, issuances of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay all or any lesser outstanding amounts due under such holder’s Note. The Notes include covenants, representations, warranties, other payment obligations and agreements by the Company including, without limitation, most-favored nation rights, rights of participation and first refusal and exchange rights. In connection with the issuance of the Notes, the Company issued Warrants to purchase in the aggregate 767,783 shares of its common stock at an initial exercise price of $24.00 per share. The Warrants may be exercised for a period of five years from the Trigger Date, provided that, if prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall be cancelled or (ii) prepays a holder’s Note(s) in whole or in part, such holder’s pro-rata number of Warrants shall be cancelled. The fair value of the Warrants was $3,700,632, of which $2,379,182 was recorded as a debt discount, which is being amortized to interest expense over the term of the Warrants, and $1,321,450 was recorded as a loss on debt extinguishment. The Company calculated the fair value of the Warrants utilizing the Black-Scholes valuation model with the following assumptions: volatility of 88.98% 0.86% 5.75 zero In connection with the April and May 2021 sales of the $4,250,000 aggregate principal amount of the Notes, the Company incurred debt issuance costs of $116,000, which were recorded as a debt discount and are being amortized to interest expense over the term of the Notes using the effective interest rate method. The interest expense attributable to the debt discount, comprising the debt issuance costs and Warrants, during the three and six months ended September 30, 2021 was $485,820 and $824,439, respectively. The $6,610,550 aggregate principal amount of Notes are due and payable in full in the first quarter of fiscal 2023. Subsequent to the Trigger Date, the Notes can be converted into 767,783	NOTE 3 – NOTES PAYABLE PPP Note On April 24, 2020, the Company received a $368,780 unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was established under the U.S. government’s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration Paycheck Protection Program Note (the Agreement) with the Lender evidencing the PPP Note. The full amount of the PPP Note is due in April 2022. Interest will accrue on the outstanding principal balance of the PPP Note at a fixed rate of 1.0% per annum, which shall be deferred for 10 months after the covered period during which the Company used the proceeds. The Company may prepay principal of the PPP Note at any time in any amount without penalty. The Agreement contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties or provisions of the PPP Note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts owing from the Company, and/or filing suit and obtaining judgment against the Company. The Company applied to the Lender for forgiveness of the PPP Note in October 2020, and the amount which may be forgiven will be equal to the sum of the payroll and benefit costs and covered rent and utility payments incurred by the Company, as calculated in accordance with the terms of the CARES Act. Convertible Promissory Notes In February and March 2021, the Company sold $2,210,000 of convertible promissory notes (the Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended (the 2021 Placement). The Notes bear interest at an annual rate of 12%, and interest is accrued or payable monthly in cash. The Notes mature on September 30, 2021 (the Maturity Date) and may be prepaid prior to the Maturity Date. The aggregate principal amount of the Notes plus accrued but unpaid interest thereon shall automatically convert upon the closing of an offering of the Company’s equity securities to investors or a strategic corporate investor resulting in aggregate gross proceeds to the Company of at least $5,000,000 (excluding conversion of the Notes or other convertible securities issued for capital raising purposes) (a Qualified Financing). In the event of a Qualified Financing, all such outstanding principal and accrued interest shall convert into the same equity securities purchased by and on the same terms and conditions as the other investors in such Qualified Financing at a conversion price equal to 80% (a 20% discount) of the lowest price paid per unit or share by investors in the Qualified Financing. In the event that additional bridge financing is obtained by the Company, the Notes shall convert into the same securities and on the same terms and conditions as the other investors therein and all such purchases will be treated as one, single round of financing going forward. As of March 31, 2021, the Notes could be converted into 770,305 shares of common stock, excluding the effects of any payments of interest in kind. At any time on or following the Maturity Date, the holders of the Notes may demand repayment of the Notes, and the Company shall repay the outstanding aggregate principal amount plus accrued but unpaid interest thereon. The holders of the Notes, however, retain the right for 30 days after the Maturity Date to convert all or part of the aggregate principal amount plus accrued but unpaid interest on the Notes into the Company’s common stock at the conversion price of $2.87 per share or at a 20% discount to any financing consummated during the 30-day period following the Maturity Date. If a Qualified Financing has not occurred immediately prior to the consummation of a Change of Control (as defined below), the Note holders shall have the option of either (i) converting all or any portion of the aggregate principal amount of the Notes plus accrued but unpaid interest thereon into common stock of the Company at a conversion price equal to $2.87 per share or (ii) having the Company repay the aggregate principal amount of the Notes and accrued but unpaid interest. The term “Change of Control” means (i) a consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, other than any such consolidation, merger or reorganization in which the shares of capital stock of the Company immediately prior to such consolidation, merger or reorganization continue to represent a majority of the voting power of the surviving entity immediately after such consolidation, merger or reorganization; (ii) any transaction or series of related transactions to which the Company is a party in which in excess of 50% of the Company’s voting power is transferred; (iii) the sale or transfer of all or substantially all of the Company’s assets, or the exclusive license of all or substantially all of the Company’s material intellectual property; or (iv) the dissolution and winding up of the Company. The Company incurred debt issuance costs of $88,800, which were recorded as a debt discount and are being amortized to interest expense over the term of the Notes using the effective interest rate method. The interest expense related to the debt discount during the year ended March 31, 2021 was approximately $13,000.

STOCKHOLDERS_ EQUITY (DEFICIT)

STOCKHOLDERS’ EQUITY (DEFICIT) & STOCK-BASED COMPENSATION	6 Months Ended	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Equity [Abstract]
STOCKHOLDERS’ EQUITY (DEFICIT) & STOCK-BASED COMPENSATION	NOTE 5 – STOCKHOLDERS’ EQUITY (DEFICIT) & STOCK-BASED COMPENSATION During the six months ended September 30, 2021, the Company issued 20,000 5,472 Amended 2017 Equity Incentive Plan In October 2017, the Company’s board of directors (the Board) approved the 2017 Equity Incentive Plan (the Plan) with 1,000,000 333,334 1,333,334 Stock-Based Compensation Expense The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant date fair value. The unamortized compensation cost, as of September 30, 2021, was $ 5,988,541 three years During the six months ended September 30, 2021, the Company granted options to purchase 457,157 43,039 5,464,619 845,979 The following assumptions were used in the fair value method calculations: Schedule of Fair Value Assumptions Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Risk-free interest rates 0.8% 0.98% 0.28% 0.37% 0.8% 0.98% 0.28% 0.37% Volatility 367% 370% 88% 127% 89% 370% 88% 128% Expected life (years) 5.0 6.2 5.0 6.0 5.0 6.2 5.0 6.0 Dividend yield — — — — The fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts for forfeitures as they occur. A summary of stock option activity under the Plan is presented below: Schedule of Stock Option activity Options Outstanding Weighted Shares Average Available Number of Exercise for Grant Shares Prices Balance at March 31, 2021 136,082 1,197,252 $ 5.25 Options granted (60,774 ) 60,774 12.69 Share awards (1,836 ) — — Options cancelled and returned to the Plan 7,547 (7,547 ) 8.61 Balance at June 30, 2021 81,089 1,250,479 5.58 Additional shares authorized under the Plan 1,333,334 — — Options granted (396,384 ) 396,384 12.15 Share awards (3,636 ) — — Options cancelled and returned to the Plan 49,213 (49,213 ) 7.02 Balance at September 30, 2021 1,063,546 1,597,650 7.17 There were no stock options exercised during the six months ended September 30, 2021 and 2020. The following table summarizes the range of outstanding and exercisable options as of September 30, 2021: Schedule of Outstanding and Exercisable Option, Range Options Outstanding Options Exercisable Range of Exercise Price Number Weighted Weighted Number Weighted Aggregate $ 1.98 17.70 1,597,650 8.09 $ 7.17 869,668 $ 4.62 $ 4,022,239 The intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company’s principal trading market over the exercise price of the option at September 30, 2021. The Company is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise of stock options as financing cash flows in the consolidated statements of cash flows. For the six months ended September 30, 2021 and 2020, there were no such tax benefits associated with the exercise of stock options.	NOTE 5 – STOCK-BASED COMPENSATION Equity Compensation Plan In October 2017, the Company’s board of directors (the Board) approved the 2017 Equity Incentive Plan (the 2017 Plan) with 3,000,000 shares of common stock reserved for issuance. In January 2020, the Board approved an amendment to the 2017 Plan to increase the number of shares reserved for issuance by 1,000,000 shares. Under the 2017 Plan, eligible employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards and restricted stock units. The 2017 Plan is administered by the Board or, in the alternative, a committee designated by the Board. The exercise or purchase price of a stock option shall be calculated as follows: (i) In the case of an incentive stock option, (a) granted to employees, who, at the time of the grant of such incentive stock option own stock representing more than 10% of the voting power of all classes of stock of the Company, the per share exercise price shall be not less than 110% of the fair market value per share on the date of grant; or (b) granted to employees, other than to employees, described in the preceding clause, the per share exercise price shall be not less than 100% of the fair market value per share on the date of grant; (ii) In the case of a non-qualified stock option, the per share exercise price shall be not less than 100% of the fair market value per share on the date of grant unless otherwise determined by the Board; and (iii) In the case of other grants, such price as determined by the Board. The Board is responsible for determining the consideration to be paid for the shares of common stock to be issued upon exercise or purchase. The 2017 Plan generally does not allow for the transfer of awards, and the Board may amend, suspend or terminate the 2017 Plan at any time. Stock-Based Compensation Expense The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant date fair value. The unamortized compensation cost, as of March 31, 2021 was $2,242,352 related to stock options and is expected to be recognized as expense over a weighted-average period of approximately 2 years. During the year ended March 31, 2021, options granted to purchase shares of its common stock to employees, directors and consultants had 10-year terms and a grant-date fair value of $1,101,737. Options to purchase 10,476 shares vested immediately on the respective grant dates. The following assumptions were used in the fair-value method calculations Year ended March 31, 2021 2020 Risk-free interest rates 0.28% 0.71% 0.77% 2.37% Volatility 87% 127% 86% 103% Expected life (years) 5.0 6.0 5.0 6.0 Dividend yield —% —% The fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts for forfeitures as they occur. A summary of stock option activity Shares Options Outstanding Available Number of Weighted Average for Grant Shares Exercise Price Balance at March 31, 2019 490,031 509,969 2.56 Additional shares authorized under the Plan 333,334 — — Options granted (572,402 ) 572,402 6.75 Options cancelled and returned to the Plan 23,056 (23,056 ) 6.75 Balance at March 31, 2020 274,019 1,059,315 4.74 Options granted (163,492 ) 163,492 8.64 Options cancelled and returned to the Plan 25,555 (25,555 ) 6.75 Balance at March 31, 2021 136,082 1,197,252 5.25 There were no stock options exercised during the years ended March 31, 2021 and 2020. The following table summarizes the range of outstanding and exercisable options Options Outstanding Options Exercisable Range of Exercise Price Number Weighted Weighted Number Weighted Aggregate $ 1.98 9.48 1,197,252 8.25 $ 5.25 742,913 $ 3.96 $ 8,763,260 The intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company’s principal trading market over the exercise price of the option. The Company is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise of stock options as financing cash flows in the consolidated statements of cash flows. For the years ended March 31, 2021 and 2020, there were no such tax benefits associated with the exercise of stock options.

INCOME TAXES

INCOME TAXES	6 Months Ended	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 6 – INCOME TAXES The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance. The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns for fiscal 2016 to fiscal 2020 may be subject to examination by the U.S. federal and state tax authorities. As of September 30, 2021, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.	NOTE 7 – INCOME TAXES The income tax provision (benefit) Year Ended March 31, 2021 2020 Current portion: Federal $ — $ — State 1,600 1,600 Current 1,600 1,600 Deferred portion: Federal (1,931,390 ) (1,180,434 ) State (576,868 ) (391,865 ) Deferred (2,508,258 ) (1,572,299 ) Change in valuation allowance 2,508,258 1,572,299 Provision for income taxes $ 1,600 $ 1,600 As of March 31, 2021, the Company had net operating loss carryforwards (NOLs) of approximately $ 13,954,000 14,019,000 The Company also had federal research and development tax credit carryforwards of approximately $ 535,000 141,000 A reconciliation of income taxes provided at the federal statutory Year Ended March 31, 2021 2020 Federal statutory rate (21 )% (21 )% State tax rate, net of federal benefit (7 )% (7 )% Permanent differences — % — % Research and development tax credits (6 )% (3 )% Section 179 assets — % — % Change in valuation allowance 34 % 31 % Effective income tax rate — % — % Significant components of the Company’s deferred tax assets and liabilities March 31, 2021 2020 Net operating loss carryforwards $ 3,909,434 $ 1,965,118 Stock-based compensation expense 554,892 364,989 Property and equipment (18,039 ) 6,842 Reserves, accruals & other (79,878 ) (7,181 ) Research and development tax credits 646,296 237,716 Total deferred tax assets 5,012,705 2,567,484 Less: valuation allowance (5,012,705 ) (2,567,484 ) Deferred tax assets, net $ — $ — Based on the available information and other factors, management believes it is more likely than not that the net deferred tax assets at March 31, 2021 and 2020, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred tax assets at March 31, 2021 and 2020. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s consolidated financial statements at March 31, 2021 and 2020. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 7 – RELATED PARTY TRANSACTIONS In February 2021, the Company’s chairman of the Board and president and an existing investor, who is represented by a member of the Company’s board of directors, purchased $100,000 and $1,000,000, aggregate principal amount of the Original Notes, respectively. Effective April 30, 2021, the related party holders entered into revocation agreements with the Company pursuant to which their collective $ 1,100,000 50,091 1,026,630 and $ 102,663 , respectively, with $ 51,640 and $ 5,164 of interest payable thereon. For the three months ended September 30, 2021, the Company incurred interest expense of approximately $ 31,105 and $ 3,100 , respectively, and for the six months ended September 30, 2021, the Company incurred interest expense of approximately $ 51,600 and $ 5,160 , respectively, on the related party holder Notes. In May 2021, a member of the Board purchased $ 200,000 4,000 10,060 10,060 of interest was payable by the Company on the Director Note.	NOTE 11 – RELATED PARTY TRANSACTIONS Consulting Services During the year ended March 31, 2020, the Company entered into consulting agreements with a member of its board of directors. Under the consulting agreements, during the year ended March 31, 2020, the Company paid the director consulting fees of $140,625 2021 Placement The Company’s chief executive officer and an existing investor, which is represented by a member of the Company’s board of directors, purchased $100,000 and $1,000,000, respectively, aggregate principal amount of the Notes (the Related Party Notes) in the 2021 Placement. As of March 31, 2021, $1,677 and $16,767 of interest was payable by the Company on the Related Party Notes to its chief executive officer and to the investor, respectively.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 – COMMITMENTS AND CONTINGENCIES Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Indemnification In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the Company’s consolidated financial statements for the six months ended September 30, 2021 and 2020 related to these indemnifications. The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements, and no claims for payment have been made under such agreements.	NOTE 10 – COMMITMENTS AND CONTINGENCIES Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Indemnification In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the Company’s consolidated financial statements for the years ended March 31, 2021 and 2020 related to these indemnifications. The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 – SUBSEQUENT EVENTS Officer Stock Purchases On October 28, 2021, the Company entered into purchase agreements with two of its executive officers, providing for the sale and issuance by the Company of 30,864 250,000 Credit Facility and Security Agreement On October 28, 2021, the Company issued a secured promissory note (the Bridge Note) to Manchester Explorer, L.P. (Manchester) that provides the Company with a $ 3,000,000 The principal amount of the Bridge Note and interest due thereon is payable to Manchester no later than the earlier of: (i) the Maturity Date and (ii) the date on which the Company has received proceeds in excess of $12,000,000 from a transaction or series of related transactions occurring prior to the Maturity Date, which such transactions constitute equity financings or other issuances of the Company's equity securities. Provided that no Event of Default (as such term is defined in the Bridge Note) has occurred, on any date prior to the Maturity Date, upon no less than three days written notice by the Company specifying the draw amount, Manchester will advance the draw amount to the Company. No draw amount can be in an amount less than $100,000 or exceed an amount equal to $3,000,000 minus the aggregate principal amount outstanding under the Note at the time of such draw request. If an Event of Default occurs and is continuing, Manchester may declare all of the Bridge Note, including any interest and other amounts due, to be due and payable immediately. In connection with the issuance of the Bridge Note, on October 28, 2021, the Company entered into a security agreement with Manchester under which the Company granted Manchester a continuing and unconditional first priority security interest in and to any and all of the Company’s property of any kind or description, tangible or intangible, wheresoever located and whether now existing or hereafter arising or acquired. On November 24, 2021 the Company filed an Amendment to the Articles of Incorporation to effectuate a reverse split of the Company’s issued and outstanding common stock at an exchange ratio of 1-for-3. The reverse stock split was effective as of November 29, 2021. All share and per share data in the condensed consolidated financial statements and footnotes has been retroactively restated to reflect the effects of the reverse stock split.	NOTE 12 – SUBSEQUENT EVENTS Convertible Promissory Notes Subsequent to March 31, 2021, the Company issued an additional $4,250,000 of the Notes in the 2021 Placement pursuant to a Securities Purchase Agreement between the Company and each investor (the SPA) and warrants to purchase shares of its common stock (the Warrants). The Notes are unsecured obligations of the Company with each Note having a stated maturity date of 12 months from its issue date (the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity, provided that, if the Company fails to pay any amounts when due under a Note, the interest rate increases to the greater of 16% or the maximum amount permitted by law. Each Note may be prepaid at the Company’s option during the first 270 calendar days following its Issue Date (the 270 th If the Notes remain outstanding after the Trigger Date, the Notes may be converted into shares of the Company’s common stock at an initial conversion price of $8.61 per share; provided, that a Note holder may not convert any portion of its Note that would cause it to beneficially own in excess of 4.99% of the Company’s outstanding common stock. The conversion price and number of shares of Company common stock issuable upon conversion of the Notes will be subject to adjustment from time to time for any subdivision or consolidation of shares and other standard dilutive and certain other corporate events, as provided in the Notes. Subject to certain Exempt Issuances (as defined in the Notes), if at any time while a Note is outstanding, the Company sells, issues or grants any shares of its common stock or other securities entitling the holder to acquire shares of the Company’s common stock at a price per share less than the then conversion price, such conversion price shall be reduced to such lesser price, and the number of shares of the Company’s common stock issuable upon conversion of the Notes shall be increased, as provided in the Notes. If the Company completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital Raise), each Note holder will be required to convert its Adjusted Note Amount into the securities of such Qualified Capital Raise. For purposes hereof, Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued but unpaid interest on a Note, multiplied by (ii) 1.25. The Notes contain a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal or interest thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v) material restatements of the Company’s consolidated financial statements filed with the SEC, (vi) a holder’s inability to rely on Rule 144 for sales of shares underlying the Notes, (vii) the Company’s common stock is suspended or halted from trading and/or fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the Nasdaq Stock Market, the New York Stock Exchange, or the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement covering the resale of shares of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date, (ix) failure to cause such registration statement to become effective within 120 calendar days following the Issue Date, or (x) certain merger consolidations, business combinations and sales of all or substantially all of the Company’s assets in the event the Company is not the survivor of such transaction. Upon an Event of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required to pay such Noteholder the product of (i) all then outstanding principal amount and accrued but unpaid interest thereon, multiplied by (ii) 125%; and all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder, in the event the Company receive cash proceeds as a result of certain events including, but not limited to, from customers, issuances of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay all or any lesser outstanding amounts due under such holder’s Note. The Notes also includes various covenants, including negative covenants, representations, warranties, other payment obligations and agreements by the Company including, without limitation, most-favored nation clauses, rights of participation and first refusal and exchange rights. In connection with the issuance of the Notes, the Company issued Warrants to purchase 761,912 shares of its common stock (Warrant Shares) at an initial exercise price of $24.00 per share. The Warrants may be exercised for a period of 5 years from the Trigger Date. In the event that, prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall be cancelled or (ii) prepays a holder’s Note(s) in whole or in part, such holder’s pro-rata number of its Warrants shall be cancelled. Effective April 30, 2021, each of the holders of the $2,210,000 of Notes outstanding at March 31, 2021 entered into a revocation and replacement agreement with the Company (the Revocation Agreement). Under the terms of the Revocation Agreement, the $2,210,000 of Notes and accrued interest of $50,091 were replaced with new Notes consistent with the terms described above. In May 2021, a member of the Board purchased $200,000 of the Notes. PPP Note As a result of the Company’s request for loan forgiveness, on May 29, 2021, the Company was notified that the outstanding principal and accrued interest for the PPP Note was forgiven in full by the U.S. Small Business Administration.

CONSOLIDATED BALANCE SHEET DETA

CONSOLIDATED BALANCE SHEET DETAIL	12 Months Ended
	Mar. 31, 2021
Consolidated Balance Sheet Detail
CONSOLIDATED BALANCE SHEET DETAIL	NOTE 2 – CONSOLIDATED BALANCE SHEET DETAIL Schedule of Property Plant And Equipment March 31, Property and equipment, net: 2021 2020 Leasehold improvements $ 139,197 $ 139,197 Office equipment 56,476 49,724 Computer equipment and software 52,383 51,882 Machinery and equipment 202,993 112,198 Property and equipment, gross 451,049 353,001 Less: accumulated depreciation and amortization (152,091 ) (51,693 ) Property and equipment, net $ 298,958 $ 301,308 Schedule of Accured Expenses March 31, Accrued expenses: 2021 2020 Accrued wages and bonus $ 372,563 $ 198,160 Accrued placement fees 88,800 — Accrued interest 27,538 — Other 11,047 4,000 Accrued expenses $ 499,948 $ 202,160

NOTES PAYABLE

NOTES PAYABLE	6 Months Ended	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 4 – CONVERTIBLE PROMISSORY NOTES From February through April 2021, the Company sold $2,310,000 of convertible promissory notes (each an Original Notes and, collectively, the Original Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between each holder of an Original Note and the Company (the Revocation Agreement), the $2,310,000 of Original Notes and accrued interest thereon as of April 30, 2021 were replaced with $2,360,550 aggregate principal amount of new Notes (as defined below). The Company accounted for the replacement of the Original Notes in accordance with ASC 470 and recorded a loss on extinguishment of $ 1,321,450 70,647 In April and May 2021, pursuant to a Securities Purchase Agreement by and between the Company and each investor (the SPA), the Company sold to investors $ 4,250,000 th Notes outstanding after the Trigger Date may be converted into shares of the Company’s common stock at an initial conversion price of $8.61 per share; provided that a Note holder may not convert any portion of its Note that would cause it to beneficially own in excess of 4.99% of the Company’s outstanding common stock. The conversion price and number of shares of Company common stock issuable upon conversion of the Notes are subject to adjustment from time to time for subdivisions and consolidations of shares and other standard dilutive and corporate events, as provided in the Notes. Subject to certain Exempt Issuances (as defined in the Notes), if while a Note is outstanding, the Company sells, issues or grants any shares of its common stock or other securities to acquire shares of common stock at a price per share less than the then conversion price, such conversion price shall be reduced to such lesser price, and the number of conversion shares issuable upon conversion of the Notes shall be increased, as provided in the Notes. If the Company completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital Raise, as defined in the Notes), each Note holder will be required to convert its Adjusted Note Amount (as defined below) into the securities of such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued interest on a Note, multiplied by (ii) 1.25. The Notes contain a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal or interest thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v) material restatements of the Company’s consolidated financial statements filed with the SEC, (vi) a holder’s inability to rely on Rule 144 for sales of shares underlying the Notes, (vii) the Company’s common stock is suspended or halted from trading and/or fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the Nasdaq Stock Market, the New York Stock Exchange, or the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement covering the resale of shares of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date, (ix) failure to cause such registration statement to become effective within 120 calendar days following the Issue Date, or (x) certain mergers consolidations, business combinations and sales of all or substantially all of the Company’s assets in the event the Company is not the survivor of such transaction. Upon an Event of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required to pay such Note holder the sum of (i) the product of (a) all then outstanding principal amount and accrued interest thereon, multiplied by (b) 125%; and (ii) all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder, in the event the Company receives cash proceeds as a result of certain events, including, but not limited to, payments from customers, issuances of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay all or any lesser outstanding amounts due under such holder’s Note. The Notes include covenants, representations, warranties, other payment obligations and agreements by the Company including, without limitation, most-favored nation rights, rights of participation and first refusal and exchange rights. In connection with the issuance of the Notes, the Company issued Warrants to purchase in the aggregate 767,783 shares of its common stock at an initial exercise price of $24.00 per share. The Warrants may be exercised for a period of five years from the Trigger Date, provided that, if prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall be cancelled or (ii) prepays a holder’s Note(s) in whole or in part, such holder’s pro-rata number of Warrants shall be cancelled. The fair value of the Warrants was $3,700,632, of which $2,379,182 was recorded as a debt discount, which is being amortized to interest expense over the term of the Warrants, and $1,321,450 was recorded as a loss on debt extinguishment. The Company calculated the fair value of the Warrants utilizing the Black-Scholes valuation model with the following assumptions: volatility of 88.98% 0.86% 5.75 zero In connection with the April and May 2021 sales of the $4,250,000 aggregate principal amount of the Notes, the Company incurred debt issuance costs of $116,000, which were recorded as a debt discount and are being amortized to interest expense over the term of the Notes using the effective interest rate method. The interest expense attributable to the debt discount, comprising the debt issuance costs and Warrants, during the three and six months ended September 30, 2021 was $485,820 and $824,439, respectively. The $6,610,550 aggregate principal amount of Notes are due and payable in full in the first quarter of fiscal 2023. Subsequent to the Trigger Date, the Notes can be converted into 767,783	NOTE 3 – NOTES PAYABLE PPP Note On April 24, 2020, the Company received a $368,780 unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was established under the U.S. government’s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration Paycheck Protection Program Note (the Agreement) with the Lender evidencing the PPP Note. The full amount of the PPP Note is due in April 2022. Interest will accrue on the outstanding principal balance of the PPP Note at a fixed rate of 1.0% per annum, which shall be deferred for 10 months after the covered period during which the Company used the proceeds. The Company may prepay principal of the PPP Note at any time in any amount without penalty. The Agreement contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties or provisions of the PPP Note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts owing from the Company, and/or filing suit and obtaining judgment against the Company. The Company applied to the Lender for forgiveness of the PPP Note in October 2020, and the amount which may be forgiven will be equal to the sum of the payroll and benefit costs and covered rent and utility payments incurred by the Company, as calculated in accordance with the terms of the CARES Act. Convertible Promissory Notes In February and March 2021, the Company sold $2,210,000 of convertible promissory notes (the Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended (the 2021 Placement). The Notes bear interest at an annual rate of 12%, and interest is accrued or payable monthly in cash. The Notes mature on September 30, 2021 (the Maturity Date) and may be prepaid prior to the Maturity Date. The aggregate principal amount of the Notes plus accrued but unpaid interest thereon shall automatically convert upon the closing of an offering of the Company’s equity securities to investors or a strategic corporate investor resulting in aggregate gross proceeds to the Company of at least $5,000,000 (excluding conversion of the Notes or other convertible securities issued for capital raising purposes) (a Qualified Financing). In the event of a Qualified Financing, all such outstanding principal and accrued interest shall convert into the same equity securities purchased by and on the same terms and conditions as the other investors in such Qualified Financing at a conversion price equal to 80% (a 20% discount) of the lowest price paid per unit or share by investors in the Qualified Financing. In the event that additional bridge financing is obtained by the Company, the Notes shall convert into the same securities and on the same terms and conditions as the other investors therein and all such purchases will be treated as one, single round of financing going forward. As of March 31, 2021, the Notes could be converted into 770,305 shares of common stock, excluding the effects of any payments of interest in kind. At any time on or following the Maturity Date, the holders of the Notes may demand repayment of the Notes, and the Company shall repay the outstanding aggregate principal amount plus accrued but unpaid interest thereon. The holders of the Notes, however, retain the right for 30 days after the Maturity Date to convert all or part of the aggregate principal amount plus accrued but unpaid interest on the Notes into the Company’s common stock at the conversion price of $2.87 per share or at a 20% discount to any financing consummated during the 30-day period following the Maturity Date. If a Qualified Financing has not occurred immediately prior to the consummation of a Change of Control (as defined below), the Note holders shall have the option of either (i) converting all or any portion of the aggregate principal amount of the Notes plus accrued but unpaid interest thereon into common stock of the Company at a conversion price equal to $2.87 per share or (ii) having the Company repay the aggregate principal amount of the Notes and accrued but unpaid interest. The term “Change of Control” means (i) a consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, other than any such consolidation, merger or reorganization in which the shares of capital stock of the Company immediately prior to such consolidation, merger or reorganization continue to represent a majority of the voting power of the surviving entity immediately after such consolidation, merger or reorganization; (ii) any transaction or series of related transactions to which the Company is a party in which in excess of 50% of the Company’s voting power is transferred; (iii) the sale or transfer of all or substantially all of the Company’s assets, or the exclusive license of all or substantially all of the Company’s material intellectual property; or (iv) the dissolution and winding up of the Company. The Company incurred debt issuance costs of $88,800, which were recorded as a debt discount and are being amortized to interest expense over the term of the Notes using the effective interest rate method. The interest expense related to the debt discount during the year ended March 31, 2021 was approximately $13,000.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Equity [Abstract]
STOCK-BASED COMPENSATION	NOTE 5 – STOCKHOLDERS’ EQUITY (DEFICIT) & STOCK-BASED COMPENSATION During the six months ended September 30, 2021, the Company issued 20,000 5,472 Amended 2017 Equity Incentive Plan In October 2017, the Company’s board of directors (the Board) approved the 2017 Equity Incentive Plan (the Plan) with 1,000,000 333,334 1,333,334 Stock-Based Compensation Expense The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant date fair value. The unamortized compensation cost, as of September 30, 2021, was $ 5,988,541 three years During the six months ended September 30, 2021, the Company granted options to purchase 457,157 43,039 5,464,619 845,979 The following assumptions were used in the fair value method calculations: Schedule of Fair Value Assumptions Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Risk-free interest rates 0.8% 0.98% 0.28% 0.37% 0.8% 0.98% 0.28% 0.37% Volatility 367% 370% 88% 127% 89% 370% 88% 128% Expected life (years) 5.0 6.2 5.0 6.0 5.0 6.2 5.0 6.0 Dividend yield — — — — The fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts for forfeitures as they occur. A summary of stock option activity under the Plan is presented below: Schedule of Stock Option activity Options Outstanding Weighted Shares Average Available Number of Exercise for Grant Shares Prices Balance at March 31, 2021 136,082 1,197,252 $ 5.25 Options granted (60,774 ) 60,774 12.69 Share awards (1,836 ) — — Options cancelled and returned to the Plan 7,547 (7,547 ) 8.61 Balance at June 30, 2021 81,089 1,250,479 5.58 Additional shares authorized under the Plan 1,333,334 — — Options granted (396,384 ) 396,384 12.15 Share awards (3,636 ) — — Options cancelled and returned to the Plan 49,213 (49,213 ) 7.02 Balance at September 30, 2021 1,063,546 1,597,650 7.17 There were no stock options exercised during the six months ended September 30, 2021 and 2020. The following table summarizes the range of outstanding and exercisable options as of September 30, 2021: Schedule of Outstanding and Exercisable Option, Range Options Outstanding Options Exercisable Range of Exercise Price Number Weighted Weighted Number Weighted Aggregate $ 1.98 17.70 1,597,650 8.09 $ 7.17 869,668 $ 4.62 $ 4,022,239 The intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company’s principal trading market over the exercise price of the option at September 30, 2021. The Company is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise of stock options as financing cash flows in the consolidated statements of cash flows. For the six months ended September 30, 2021 and 2020, there were no such tax benefits associated with the exercise of stock options.	NOTE 5 – STOCK-BASED COMPENSATION Equity Compensation Plan In October 2017, the Company’s board of directors (the Board) approved the 2017 Equity Incentive Plan (the 2017 Plan) with 3,000,000 shares of common stock reserved for issuance. In January 2020, the Board approved an amendment to the 2017 Plan to increase the number of shares reserved for issuance by 1,000,000 shares. Under the 2017 Plan, eligible employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards and restricted stock units. The 2017 Plan is administered by the Board or, in the alternative, a committee designated by the Board. The exercise or purchase price of a stock option shall be calculated as follows: (i) In the case of an incentive stock option, (a) granted to employees, who, at the time of the grant of such incentive stock option own stock representing more than 10% of the voting power of all classes of stock of the Company, the per share exercise price shall be not less than 110% of the fair market value per share on the date of grant; or (b) granted to employees, other than to employees, described in the preceding clause, the per share exercise price shall be not less than 100% of the fair market value per share on the date of grant; (ii) In the case of a non-qualified stock option, the per share exercise price shall be not less than 100% of the fair market value per share on the date of grant unless otherwise determined by the Board; and (iii) In the case of other grants, such price as determined by the Board. The Board is responsible for determining the consideration to be paid for the shares of common stock to be issued upon exercise or purchase. The 2017 Plan generally does not allow for the transfer of awards, and the Board may amend, suspend or terminate the 2017 Plan at any time. Stock-Based Compensation Expense The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant date fair value. The unamortized compensation cost, as of March 31, 2021 was $2,242,352 related to stock options and is expected to be recognized as expense over a weighted-average period of approximately 2 years. During the year ended March 31, 2021, options granted to purchase shares of its common stock to employees, directors and consultants had 10-year terms and a grant-date fair value of $1,101,737. Options to purchase 10,476 shares vested immediately on the respective grant dates. The following assumptions were used in the fair-value method calculations Year ended March 31, 2021 2020 Risk-free interest rates 0.28% 0.71% 0.77% 2.37% Volatility 87% 127% 86% 103% Expected life (years) 5.0 6.0 5.0 6.0 Dividend yield —% —% The fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts for forfeitures as they occur. A summary of stock option activity Shares Options Outstanding Available Number of Weighted Average for Grant Shares Exercise Price Balance at March 31, 2019 490,031 509,969 2.56 Additional shares authorized under the Plan 333,334 — — Options granted (572,402 ) 572,402 6.75 Options cancelled and returned to the Plan 23,056 (23,056 ) 6.75 Balance at March 31, 2020 274,019 1,059,315 4.74 Options granted (163,492 ) 163,492 8.64 Options cancelled and returned to the Plan 25,555 (25,555 ) 6.75 Balance at March 31, 2021 136,082 1,197,252 5.25 There were no stock options exercised during the years ended March 31, 2021 and 2020. The following table summarizes the range of outstanding and exercisable options Options Outstanding Options Exercisable Range of Exercise Price Number Weighted Weighted Number Weighted Aggregate $ 1.98 9.48 1,197,252 8.25 $ 5.25 742,913 $ 3.96 $ 8,763,260 The intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company’s principal trading market over the exercise price of the option. The Company is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise of stock options as financing cash flows in the consolidated statements of cash flows. For the years ended March 31, 2021 and 2020, there were no such tax benefits associated with the exercise of stock options.

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Mar. 31, 2021
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 6 – STOCKHOLDERS’ EQUITY Private Placement Between March and December 2020, the Company completed a private placement of shares of its common stock (the 2020 Placement). The Company sold 320,796

ROYALTY AGREEMENT

ROYALTY AGREEMENT	12 Months Ended
	Mar. 31, 2021
Royalty Agreement
ROYALTY AGREEMENT	NOTE 8 – ROYALTY AGREEMENT In July 2017, the Company entered into a royalty agreement with its founder, chief executive officer and major shareholder (the Founder). Pursuant to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras in return for future royalty payments on the Company’s product. The Company is obligated to make royalty payments under the agreement to the Founder on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $0.75 on each sale of a royalty product or (b) 5% of the gross sale price of the royalty product, whichever is less. The royalty payments will cease, and the agreement will terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant to the agreement, reaches $10,000,000. The Company has the option to terminate the agreement at any time upon payment, to the Founder, of the difference between total royalty payments actually made to him to date and the sum of $10,000,000. All payments of the royalties, if due, for the preceding quarter, will be made by the Company to the Founder within thirty days after the end of each calendar quarter.

RETIREMENT SAVINGS PLAN

RETIREMENT SAVINGS PLAN	12 Months Ended
	Mar. 31, 2021
Retirement Savings Plan
RETIREMENT SAVINGS PLAN	NOTE 9 – RETIREMENT SAVINGS PLAN Effective March 2020, the Company adopted the Modular Medical, Inc. 401(k) Plan (the Savings Plan), which qualifies as a thrift plan under Section 401(k) of the Internal Revenue Code. Full-time and part-time employees who are at least 21 years of age are eligible to participate in the Savings Plan at the time of hire. Participants may contribute up to 15% of their earnings to the Savings Plan. The Plan became effective and began accepting participant contributions in April 2020.

THE COMPANY AND SUMMARY OF SI_2

THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity	Liquidity Financial Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15), Going Concern The Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent commercialization of its product. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant product revenues to achieve profitability. The Company’s expected operating losses and cash burn and the need to repay the convertible promissory notes and accrued interest in the first half of 2022 raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. As disclosed in note 9, the Company recently sold shares of its common stock to two of its officers, obtained access to a credit facility and filed a registration statement to offer shares of its common stock. The Company’s operating needs include the planned costs to operate its business, including amounts required to repay its convertible promissory notes (if not converted), fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. These condensed consolidated financial statements do not include any adjustments that might result from this uncertainty.	Liquidity Financial Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15), Going The Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent commercialization of its product. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. As discussed in notes 3 and 11, in February 2021, the Company commenced a private placement of its convertible promissory notes to investors to fund its operations. In addition, during fiscal 2021, the Company obtained additional equity financing through a private placement of its common stock (see note 6), and the Company obtained a loan from Silicon Valley Bank in April 2020 (see notes 3 and 12). The Company’s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. These consolidated financial statements do not include any adjustments that might result from this uncertainty.
Basis of Presentation	Basis of Presentation The Company’s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2022 refers to the fiscal year ending March 31, 2022). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation. The accompanying condensed consolidated financial statements of the Company have been prepared without audit. The condensed consolidated balance sheet as of March 31, 2021 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending March 31, 2022 or for any other future period. All share and per share amounts have been presented to give retroactive effect to a 1-for-3 reverse stock split that occurred in November 2021.	Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on March 31 of each calendar year.
Use of Estimates	Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.	Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.
Reportable Segment	Reportable Segment The Company operates in one	Reportable Segment The Company operates in one business segment and uses one measurement of profitability for its business.
Research and Development	Research and Development The Company expenses research and development expenditures as incurred.	Research and Development The Company expenses research and development expenditures as incurred.
General and Administrative	General and Administrative General and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees, and office and other administrative expenses.	General and Administrative General and administrative expense consists primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and meetings and travel.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash balances at high-quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial institution failure.	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are deposited with high credit-quality institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing technology and customer requirements, limited operating history and the volatility of public markets. COVID-19 The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted.	Risks and Uncertainties The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets. COVID-19 The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and highly liquid debt instruments with original maturities of three months or less.	Cash and Cash Equivalents Cash and cash equivalents include cash in hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.
Property and Equipment	Property & Equipment Property and equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three five	Property and Equipment Property and equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three five
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: · Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. · Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. · Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement. Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses approximate fair value.	Fair Value of Financial Instruments The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: · Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. · Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. · Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement. Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.
Per-Share Amounts	Per-Share Amounts Basic net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. For the six months ended September 30, 2021 and 2020, outstanding options to purchase 1,597,650 1,160,030	Per-Share Amounts Basic net loss per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. For the years ended March 31, 2021 and 2020, 1,197,252 1,059,315
Reclassification	Reclassification Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows.
Comprehensive Loss	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and six months ended September 30, 2021 and 2020, the Company’s comprehensive loss was the same as its net loss.	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2021 and 2020, the Company’s comprehensive loss was the same as its net loss.
Recently Adopted Accounting Pronouncement	Recently Adopted Accounting Pronouncement In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an Entity’s Own Equity .
Stock-Based Compensation		Stock-Based Compensation The Company recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and projected stock option exercise behaviors.
Income Taxes		Income Taxes The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance. The Company accounts for uncertain tax positions in accordance with FASB Accounting Standards Codification (ASC) Topic 740, Income Taxes The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns from 2016 to 2020 may be subject to examination by the U.S. federal and state tax authorities. As of March 31, 2021, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.

LEASES (Tables)

LEASES (Tables)	6 Months Ended	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Leases [Abstract]
Future minimum payments under the facility operating lease, net of the lease incentive	Future minimum payments under the facility operating lease, as of September 30, 2021, are listed in the table below.	Future minimum payments under the facility operating lease, net of the lease incentive
LEASES	Operating Annual Fiscal Years lease 2022 76,716 2023 158,028 2024 40,692 Less: Imputed interest (26,613 ) Present value of lease liabilities $ 248,823
LEASES		Operating Annual Fiscal Years lease 2022 $ 153,432 2023 158,028 2024 40,692 Less: Imputed interest (42,297 ) Present value of lease liabilities $ 309,855

STOCKHOLDERS_ EQUITY (DEFICIT_2

STOCKHOLDERS’ EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Tables)	6 Months Ended	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Equity [Abstract]
Schedule of Fair Value Assumptions	The following assumptions were used in the fair value method calculations: Schedule of Fair Value Assumptions	The following assumptions were used in the fair-value method calculations
STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION	Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Risk-free interest rates 0.8% 0.98% 0.28% 0.37% 0.8% 0.98% 0.28% 0.37% Volatility 367% 370% 88% 127% 89% 370% 88% 128% Expected life (years) 5.0 6.2 5.0 6.0 5.0 6.2 5.0 6.0 Dividend yield — — — —	Year ended March 31, 2021 2020 Risk-free interest rates 0.28% 0.71% 0.77% 2.37% Volatility 87% 127% 86% 103% Expected life (years) 5.0 6.0 5.0 6.0 Dividend yield —% —%
Schedule of Stock Option activity	A summary of stock option activity under the Plan is presented below: Schedule of Stock Option activity	A summary of stock option activity
STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details 2)	Options Outstanding Weighted Shares Average Available Number of Exercise for Grant Shares Prices Balance at March 31, 2021 136,082 1,197,252 $ 5.25 Options granted (60,774 ) 60,774 12.69 Share awards (1,836 ) — — Options cancelled and returned to the Plan 7,547 (7,547 ) 8.61 Balance at June 30, 2021 81,089 1,250,479 5.58 Additional shares authorized under the Plan 1,333,334 — — Options granted (396,384 ) 396,384 12.15 Share awards (3,636 ) — — Options cancelled and returned to the Plan 49,213 (49,213 ) 7.02 Balance at September 30, 2021 1,063,546 1,597,650 7.17	Shares Options Outstanding Available Number of Weighted Average for Grant Shares Exercise Price Balance at March 31, 2019 490,031 509,969 2.56 Additional shares authorized under the Plan 333,334 — — Options granted (572,402 ) 572,402 6.75 Options cancelled and returned to the Plan 23,056 (23,056 ) 6.75 Balance at March 31, 2020 274,019 1,059,315 4.74 Options granted (163,492 ) 163,492 8.64 Options cancelled and returned to the Plan 25,555 (25,555 ) 6.75 Balance at March 31, 2021 136,082 1,197,252 5.25
Schedule of Outstanding and Exercisable Option, Range	The following table summarizes the range of outstanding and exercisable options as of September 30, 2021: Schedule of Outstanding and Exercisable Option, Range	The following table summarizes the range of outstanding and exercisable options
STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details 3)	Options Outstanding Options Exercisable Range of Exercise Price Number Weighted Weighted Number Weighted Aggregate $ 1.98 17.70 1,597,650 8.09 $ 7.17 869,668 $ 4.62 $ 4,022,239	Options Outstanding Options Exercisable Range of Exercise Price Number Weighted Weighted Number Weighted Aggregate $ 1.98 9.48 1,197,252 8.25 $ 5.25 742,913 $ 3.96 $ 8,763,260

CONSOLIDATED BALANCE SHEET DE_2

CONSOLIDATED BALANCE SHEET DETAIL (Tables)	12 Months Ended
	Mar. 31, 2021
Consolidated Balance Sheet Detail
Schedule of Property Plant And Equipment	Schedule of Property Plant And Equipment
CONSOLIDATED BALANCE SHEET DETAIL	March 31, Property and equipment, net: 2021 2020 Leasehold improvements $ 139,197 $ 139,197 Office equipment 56,476 49,724 Computer equipment and software 52,383 51,882 Machinery and equipment 202,993 112,198 Property and equipment, gross 451,049 353,001 Less: accumulated depreciation and amortization (152,091 ) (51,693 ) Property and equipment, net $ 298,958 $ 301,308
Schedule of Accured Expenses	Schedule of Accured Expenses
CONSOLIDATED BALANCE SHEET DETAIL (Details 2)	March 31, Accrued expenses: 2021 2020 Accrued wages and bonus $ 372,563 $ 198,160 Accrued placement fees 88,800 — Accrued interest 27,538 — Other 11,047 4,000 Accrued expenses $ 499,948 $ 202,160

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021
Equity [Abstract]
assumptions were used in the fair-value method calculations	The following assumptions were used in the fair value method calculations: Schedule of Fair Value Assumptions	The following assumptions were used in the fair-value method calculations
STOCK-BASED COMPENSATION	Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Risk-free interest rates 0.8% 0.98% 0.28% 0.37% 0.8% 0.98% 0.28% 0.37% Volatility 367% 370% 88% 127% 89% 370% 88% 128% Expected life (years) 5.0 6.2 5.0 6.0 5.0 6.2 5.0 6.0 Dividend yield — — — —	Year ended March 31, 2021 2020 Risk-free interest rates 0.28% 0.71% 0.77% 2.37% Volatility 87% 127% 86% 103% Expected life (years) 5.0 6.0 5.0 6.0 Dividend yield —% —%
stock option activity	A summary of stock option activity under the Plan is presented below: Schedule of Stock Option activity	A summary of stock option activity
STOCK-BASED COMPENSATION (Details 2)	Options Outstanding Weighted Shares Average Available Number of Exercise for Grant Shares Prices Balance at March 31, 2021 136,082 1,197,252 $ 5.25 Options granted (60,774 ) 60,774 12.69 Share awards (1,836 ) — — Options cancelled and returned to the Plan 7,547 (7,547 ) 8.61 Balance at June 30, 2021 81,089 1,250,479 5.58 Additional shares authorized under the Plan 1,333,334 — — Options granted (396,384 ) 396,384 12.15 Share awards (3,636 ) — — Options cancelled and returned to the Plan 49,213 (49,213 ) 7.02 Balance at September 30, 2021 1,063,546 1,597,650 7.17	Shares Options Outstanding Available Number of Weighted Average for Grant Shares Exercise Price Balance at March 31, 2019 490,031 509,969 2.56 Additional shares authorized under the Plan 333,334 — — Options granted (572,402 ) 572,402 6.75 Options cancelled and returned to the Plan 23,056 (23,056 ) 6.75 Balance at March 31, 2020 274,019 1,059,315 4.74 Options granted (163,492 ) 163,492 8.64 Options cancelled and returned to the Plan 25,555 (25,555 ) 6.75 Balance at March 31, 2021 136,082 1,197,252 5.25
summarizes the range of outstanding and exercisable options	The following table summarizes the range of outstanding and exercisable options as of September 30, 2021: Schedule of Outstanding and Exercisable Option, Range	The following table summarizes the range of outstanding and exercisable options
STOCK-BASED COMPENSATION (Details 3)	Options Outstanding Options Exercisable Range of Exercise Price Number Weighted Weighted Number Weighted Aggregate $ 1.98 17.70 1,597,650 8.09 $ 7.17 869,668 $ 4.62 $ 4,022,239	Options Outstanding Options Exercisable Range of Exercise Price Number Weighted Weighted Number Weighted Aggregate $ 1.98 9.48 1,197,252 8.25 $ 5.25 742,913 $ 3.96 $ 8,763,260

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
The income tax provision (benefit)	The income tax provision (benefit)
INCOME TAXES	Year Ended March 31, 2021 2020 Current portion: Federal $ — $ — State 1,600 1,600 Current 1,600 1,600 Deferred portion: Federal (1,931,390 ) (1,180,434 ) State (576,868 ) (391,865 ) Deferred (2,508,258 ) (1,572,299 ) Change in valuation allowance 2,508,258 1,572,299 Provision for income taxes $ 1,600 $ 1,600
A reconciliation of income taxes provided at the federal statutory	A reconciliation of income taxes provided at the federal statutory
INCOME TAXES (Details 2)	Year Ended March 31, 2021 2020 Federal statutory rate (21 )% (21 )% State tax rate, net of federal benefit (7 )% (7 )% Permanent differences — % — % Research and development tax credits (6 )% (3 )% Section 179 assets — % — % Change in valuation allowance 34 % 31 % Effective income tax rate — % — %
Significant components of the Company’s deferred tax assets and liabilities	Significant components of the Company’s deferred tax assets and liabilities
INCOME TAXES (Details 3)	March 31, 2021 2020 Net operating loss carryforwards $ 3,909,434 $ 1,965,118 Stock-based compensation expense 554,892 364,989 Property and equipment (18,039 ) 6,842 Reserves, accruals & other (79,878 ) (7,181 ) Research and development tax credits 646,296 237,716 Total deferred tax assets 5,012,705 2,567,484 Less: valuation allowance (5,012,705 ) (2,567,484 ) Deferred tax assets, net $ — $ —

THE COMPANY AND SUMMARY OF SI_3

THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	6 Months Ended		12 Months Ended
	Sep. 30, 2021Numbershares	Sep. 30, 2020shares	Mar. 31, 2021shares	Mar. 31, 2020shares
Number of Operating Segments | Number	1
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares	1,597,650	1,160,030	1,197,252	1,059,315
Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years		3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life	5 years		5 years

LEASES (Details)

LEASES (Details) - USD ($)	Sep. 30, 2021	Mar. 31, 2021
Leases [Abstract]
2022	$ 76,716	$ 153,432
2023	158,028	158,028
2024	40,692	40,692
Imputed interest	(26,613)	(42,297)
Present value of lease liabilities	248,823	309,855
Present value of lease liabilities	$ 248,823	$ 309,855

LEASES (Details Narrative)

LEASES (Details Narrative)	1 Months Ended	3 Months Ended			6 Months Ended		12 Months Ended
	Apr. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Jun. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Jun. 30, 2020USD ($)	Apr. 02, 2020
Leases [Abstract]
Lessee, Operating Lease, Term of Contract										39 months
Operating Leases, Rent Expense	$ 12,400	$ 26,884		$ 26,844	$ 53,768	$ 53,768	$ 107,540	$ 35,766
[custom:OperatingLeasesAnnualRentIncreasePercentange-0]										0.03
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability			$ 270,950		270,950
Lease Incentive Received									$ 139,000
[custom:CashPaidforLeaseLiabilities-0]		$ 76,716			$ 76,716

PPP NOTE (Details Narrative)

PPP NOTE (Details Narrative) - USD ($)	Sep. 30, 2021	Mar. 31, 2021	Apr. 24, 2020	Mar. 31, 2020
Ppp Note
Unsecured Debt, Current		$ 368,780	$ 368,780

CONVERTIBLE PROMISSORY NOTES (D

CONVERTIBLE PROMISSORY NOTES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	May 31, 2021
Short-term Debt [Line Items]
Gain (Loss) on Extinguishment of Debt			$ 1,321,450
Amortization of Debt Issuance Costs			$ 70,647
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate			88.98%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			0.86%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term			5 years 9 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%	0.00%
[custom:NotesAndAccuredInterestCouldBeConvertedIntoCommonStock-0]	767,783		767,783
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Convertible Notes Payable					$ 4,250,000

STOCKHOLDERS' EQUITY (DEFICIT)

STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			0.86%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term			5 years 9 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.80%	0.28%	0.80%	0.28%	0.28%	0.77%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	367.00%	88.00%	89.00%	88.00%	87.00%	86.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years	5 years	5 years	5 years	5 years	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate					0.00%	0.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.98%	0.37%	0.98%	0.37%	0.71%	2.37%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	370.00%	127.00%	370.00%	128.00%	127.00%	103.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years 2 months 12 days	6 years	6 years 2 months 12 days	6 years	6 years	6 years

STOCKHOLDERS' EQUITY (DEFICIT_2

STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details 2) - $ / shares	3 Months Ended		6 Months Ended	12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2021	Mar. 31, 2021	Mar. 31, 2020
Offsetting Assets [Line Items]
Number of Option, Beginning Balance		136,082	136,082	274,019	490,031
Number of Options, Granted				(163,492)	(572,402)
Number of Options, cancelled and returned to the Plan				(25,555)	(23,056)
Number of Option, Ending Balance				136,082	274,019
Equity Option [Member]
Offsetting Assets [Line Items]
Shares Available for Grant, Beginning Balance	81,089	136,082	136,082
Number of Option, Beginning Balance	1,250,479	1,197,252	1,197,252	1,059,315	509,969
Weighted Average Exercise Price, Beginning Balance	$ 5.58	$ 5.25	$ 5.25	$ 4.74	$ 2.56
Shares available for grant, Granted	(396,384)	(60,774)
Number of Options, Granted	396,384	60,774		163,492	572,402
Weighted Average Exercise Price, Options Granted	$ 12.15	$ 12.69		$ 8.64	$ 6.75
Shares available for grant, Awards	(3,636)	(1,836)
Shares available for grant, Cancelled and Returned to the Plan	49,213	7,547
Number of Options, cancelled and returned to the Plan	(49,213)	(7,547)		25,555	23,056
Weighted Average Exercise Price, Options cancelled and returned to the Plan	$ 7.02	$ 8.61		$ 6.75	$ 6.75
Shares available for grant, Additional Shares authorized under the Plan	1,333,334
Shares Available for Grant, Ending Balance	1,063,546	81,089	1,063,546	136,082
Number of Option, Ending Balance	1,597,650	1,250,479	1,597,650	1,197,252	1,059,315
Weighted Average Exercise Price, Ending Balance	$ 7.17	$ 5.58	$ 7.17	$ 5.25	$ 4.74

STOCKHOLDERS' EQUITY (DEFICIT_3

STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details 3) - USD ($)	6 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number			136,082	274,019	490,031
Equity Option [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,597,650	1,250,479	1,197,252	1,059,315	509,969
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	8 years 1 month 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 7.17	$ 5.58	$ 5.25	$ 4.74	$ 2.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	869,668
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 4.62
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 4,022,239
Equity Option [Member] | Minimum [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 1.98
Equity Option [Member] | Maximum [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 17.70

STOCKHOLDERS_ EQUITY (DEFICIT_3

STOCKHOLDERS’ EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended		9 Months Ended	12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Aug. 31, 2020	Jan. 31, 2020	Oct. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance										1,333,334	333,334	1,000,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 5,988,541				$ 5,988,541
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition					3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								(163,492)	(572,402)
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	$ 862,431	$ 655,920	$ 300,604	$ 344,716	$ 1,518,351	$ 645,320
Equity Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	396,384	60,774						163,492	572,402
[custom:FairValueofOptionGranted]					5,464,619
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture					$ 845,979
Employee Stock [Member] | Equity Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					43,039
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock Issued During Period, Shares, New Issues				243,299	20,000		320,796	320,796
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture	3,365	1,836			5,472
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	$ 4	$ 2
Common Stock [Member] | Employee Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					457,157

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2021	Mar. 31, 2020	May 31, 2021
Related Party Transaction [Line Items]
Interest Expense	$ 685,793		$ 1,194,670		$ 39,791
C E O And Investor [Member]
Related Party Transaction [Line Items]
Notes Cancelled	1,100,000		1,100,000
Interest Payable	$ 50,091		$ 50,091
C E O And Investor [Member] | Notes Payable Other Payables 1 [Member]
Related Party Transaction [Line Items]
Interest Payable	51,640		51,640
Notes Payable	1,026,630		1,026,630
Interest Expense	31,105	$ 3,100	5,160	51,600
C E O And Investor [Member] | Notes Payable Other Payables 2 [Member]
Related Party Transaction [Line Items]
Interest Payable	5,164		5,164
Notes Payable	102,663		102,663
Interest Expense	4,000			$ 10,060
Member Of Board [Member]
Related Party Transaction [Line Items]
Interest Payable	$ 10,060		$ 10,060
Notes Payable							$ 200,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Oct. 28, 2021	Jun. 30, 2020	Sep. 30, 2021	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Subsequent Event [Line Items]
Stock Issued During Period, Value, New Issues		$ 1,118,634			$ 1,785,882	$ 923,994
Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues		243,299	20,000	320,796	320,796
Stock Issued During Period, Value, New Issues		$ 243			$ 321
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Value, New Issues	$ 250,000
Subsequent Event [Member] | Revolving Credit Facility [Member] | Manchester Explorer L P [Member]
Subsequent Event [Line Items]
Long-term Line of Credit	$ 3,000,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	30,864

CONSOLIDATED BALANCE SHEET DE_3

CONSOLIDATED BALANCE SHEET DETAIL (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 451,049	$ 353,001
Less: accumulated depreciation and amortization	(152,091)	(51,693)
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	139,197	139,197
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	56,476	49,724
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	52,383	51,882
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 202,993	$ 112,198

CONSOLIDATED BALANCE SHEET DE_4

CONSOLIDATED BALANCE SHEET DETAIL (Details 2) - USD ($)	Sep. 30, 2021	Mar. 31, 2021	Mar. 31, 2020
Interim Period, Costs Not Allocable [Line Items]
Accrued expenses	$ 678,797	$ 499,948	$ 202,160
Accured Wages and Bonus [Member]
Interim Period, Costs Not Allocable [Line Items]
Accrued expenses		372,563	198,160
Accured Placement Fees [Member]
Interim Period, Costs Not Allocable [Line Items]
Accrued expenses		88,800
Accured Interest [Member]
Interim Period, Costs Not Allocable [Line Items]
Accrued expenses		27,538
Accrued Other Expenses [Member]
Interim Period, Costs Not Allocable [Line Items]
Accrued expenses		$ 11,047	$ 4,000

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2021	Mar. 31, 2020
Risk-free interest rates			0.86%
Expected Life (years)			5 years 9 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Risk-free interest rates	0.80%	0.28%	0.80%	0.28%	0.28%	0.77%
Volatility	367.00%	88.00%	89.00%	88.00%	87.00%	86.00%
Expected Life (years)	5 years	5 years	5 years	5 years	5 years	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate					0.00%	0.00%
Maximum [Member]
Risk-free interest rates	0.98%	0.37%	0.98%	0.37%	0.71%	2.37%
Volatility	370.00%	127.00%	370.00%	128.00%	127.00%	103.00%
Expected Life (years)	6 years 2 months 12 days	6 years	6 years 2 months 12 days	6 years	6 years	6 years

STOCK-BASED COMPENSATION (Det_2

STOCK-BASED COMPENSATION (Details 2) - $ / shares	3 Months Ended		6 Months Ended	12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2021	Mar. 31, 2021	Mar. 31, 2020
Offsetting Assets [Line Items]
Number of Option, Beginning Balance		136,082	136,082	274,019	490,031
Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period					333,334
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				(163,492)	(572,402)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period				25,555	23,056
Number of Option, Ending Balance				136,082	274,019
Equity Option [Member]
Offsetting Assets [Line Items]
Number of Option, Beginning Balance	1,250,479	1,197,252	1,197,252	1,059,315	509,969
Weighted Average Exercise Price, Beginning Balance	$ 5.58	$ 5.25	$ 5.25	$ 4.74	$ 2.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	396,384	60,774		163,492	572,402
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 12.15	$ 12.69		$ 8.64	$ 6.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	49,213	7,547		(25,555)	(23,056)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price	$ 7.02	$ 8.61		$ 6.75	$ 6.75
Number of Option, Ending Balance	1,597,650	1,250,479	1,597,650	1,197,252	1,059,315
Weighted Average Exercise Price, Ending Balance	$ 7.17	$ 5.58	$ 7.17	$ 5.25	$ 4.74

STOCK-BASED COMPENSATION (Det_3

STOCK-BASED COMPENSATION (Details 3) - USD ($)	12 Months Ended
	Mar. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2020	Mar. 31, 2019
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	136,082			274,019	490,031
Equity Option [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,197,252	1,597,650	1,250,479	1,059,315	509,969
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	8 years 4 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 5.25	$ 7.17	$ 5.58	$ 4.74	$ 2.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	742,913
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term	3 years 11 months 16 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value	$ 8,763,260
Equity Option [Member] | Minimum [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price	$ 1.98
Equity Option [Member] | Maximum [Member]
Offsetting Assets [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price	$ 9.48

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - shares	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2020	Sep. 30, 2021	Dec. 31, 2020	Mar. 31, 2021
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock Issued During Period, Shares, New Issues	243,299	20,000	320,796	320,796

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2021	Mar. 31, 2020
Current portion:
Federal
State					1,600	1,600
Current					1,600	1,600
Deferred portion:
Federal					(1,931,390)	(1,180,434)
State					(576,868)	(391,865)
Deferred					(2,508,258)	(1,572,299)
Change in valuation allowance					2,508,258	1,572,299
Provision for income taxes	$ 1,600	$ 1,600	$ 1,600	$ 1,600	$ 1,600	$ 1,600

INCOME TAXES (Details 2)

INCOME TAXES (Details 2)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Federal statutory rate	(21.00%)	(21.00%)
State tax rate, net of federal benefit	(7.00%)	(7.00%)
Permanent differences	0	0
Research and development tax credits	(6.00%)	(3.00%)
Section 179 assets	0.00%	0.00%
Change in valuation allowance	34.00%	31.00%
Effective income tax rate	0.00%	0.00%

INCOME TAXES (Details 3)

INCOME TAXES (Details 3) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 3,909,434	$ 1,965,118
Stock-based compensation expense	554,892	364,989
Property and equipment	(18,039)	6,842
Reserves, accruals & other	(79,878)	(7,181)
Research and development tax credits	646,296	237,716
Total deferred tax assets	5,012,705	2,567,484
Less: valuation allowance	(5,012,705)	(2,567,484)
Deferred tax assets, net

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative)	Mar. 31, 2021USD ($)
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry-forwards	$ 13,954,000
Research and development tax credit carryforwards	535,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry-forwards	14,019,000
Research and development tax credit carryforwards	$ 141,000